Form 4: Core Scientific Officer Sells Shares Under 10b5-1 Plan

Core Scientific, Inc. officer Todd M. Duchene reported the sale of 10,000 shares of common stock under a pre-arranged trading plan.

Summary

• Todd M. Duchene, Chief Legal and Administrative Officer of Core Scientific, Inc., reported transactions involving the sale of common stock.
• A total of 10,000 shares were sold on June 22, 2026.
• The sales were executed under a Rule 10b5-1 trading plan adopted on December 5, 2025.
• The weighted average sale price for 7,600 shares was $29.1103, with individual sales ranging from $28.61 to $29.58.
• An additional 2,400 shares were sold at a weighted average price of $29.8754, with individual sales ranging from $29.64 to $30.32.
• Following these transactions, Duchene beneficially owns 2,048,895 shares of common stock.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the insider selling, although the use of a Rule 10b5-1 plan mitigates the negative sentiment.

Negatives

• Company officer sold a significant number of shares (10,000 shares).

Risks

• The sale of shares by a key executive could be interpreted negatively by the market, potentially impacting investor confidence.
• The transactions were conducted under a Rule 10b5-1 plan, which is designed to avoid insider trading concerns, but the volume of sales may still raise questions.

Future Outlook

The filing does not contain forward-looking statements or guidance. It reports on past transactions.

Management Comments

• The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.
• The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.61 to $29.58, inclusive.
• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
• The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.64 to $30.32, inclusive.
• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

Industry Context

StockSavvy.ai notes that insider selling, even under a Rule 10b5-1 plan, can sometimes be a signal that executives believe the stock may not have significant near-term upside, or they may be diversifying their personal holdings. However, the existence of the 10b5-1 plan mitigates concerns about opportunistic trading based on non-public information.

Stakeholder Impact

• Shareholders: May view the sale by an executive with concern, potentially leading to short-term stock price pressure, though the 10b5-1 plan provides some reassurance.
• Employees: May interpret the sale as a lack of confidence from management, depending on the overall company sentiment.
• Creditors: Unlikely to be directly impacted by this specific transaction.

Next Steps

• The Reporting Person may continue to execute trades under the Rule 10b5-1 plan.
• The company may need to address any investor concerns arising from the insider selling.

Key Dates

Recommendation

The filing reports insider selling under a pre-arranged plan, which is a common practice. While insider selling can be a negative signal, the Rule 10b5-1 plan suggests the sales were planned in advance and not based on material non-public information. Without other significant negative or positive news in the filing, a 'hold' recommendation is appropriate, advising investors to monitor further developments and the company's overall performance.

Keywords

Core Scientific, CORZ, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Todd M. Duchene, Beneficial Ownership